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SIGNALING through CD28/B7 and CD40/CD40L co-
stimulatory pathways as a prerequisite for optimal 
T-cell activation has been well documented. t •2 Further-
more, unlike that through CD40/gp39. blockade of signaling 
through the CD28/B7 pathway by perioperative use of 
CTLA4-Ig fusion protein has been shown to enhance 
allograft survival and mitigate the development of chronic 
rejection (CR).3 In contrast, combined blockage of these 
two pathways has been shown to abrogate the development 
of posttransplant vasculopathy in a murine model of cardiac 
allotransplantation. l However, the utility of this latter 
model to study pathogenesis of CR is limited and, for its 
acceptance and mitigation of acute cellular rejection, the 
use of immunosuppressive drugs is required-agents them-
selves implicated in playing a role in the etiopathology of 
this lesion. It is for this purpose that we have developed an 
aortic allotransplantation (AOTx) model of CR in mice in 
which, for the acceptance of the graft, no immunosuppres-
sion is required and in which resultant changes established 
within 30 days posttransplantation are pathognomonic of 
CR.4 Reported herein is the role of blockade of costimula-
tion and the evolution of CR. 
MATERIALS AND METHODS 
AOTx was performed across the B10 (H - ObF~CPe (H - 2k) 
strain combination by a method described previously.' Recipient 
treatment is detailed in Table 1. In addition to aortic transplanta· 
tion (Tx) across untreated allogeneic (group B) and syngeneic 
(group A) recipients. those treated with irrelevant isotype-matched 
monoclonal antibodies (MAb; group C; human and hamster IgG; 
Jackson Immuno-Research Lab. West Grove. Pa) were also used as 
controls. Grafts were harvested at day 30 posttransplantation for 
histologic and immunohistochemical staining. 
RESULTS AND DISCUSSION 
Unlike group A. aortic allografts harvested from group B 
and C animals exhibited marked concentric intimal thick-
ening with corresponding narrowing of the lumen (Table 1). 
This was accompanied by variable impairment of the elastic 
membranes and deposition within the intima of fibrous 
tissue and collagen. The intimal thickening observed in 
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Table 1. Effect of Costimulatory Blockade on Development of Chronic Rejection· 
Group Treatment Intimal Thickening 
A Untreatedt 
B Untreated +++ 
C Irrelevant isotype-matched MAb; +++ 
D CTlA4-lg§ +++ 
E CTlA4-lgll +++ 
F Anti-CD40L 11 
G CTlA4-lg§ + anti-CD40L 11 ++ 
H CTlA4-lgll + anti-CD40L# 
• All aortic aliotransplants were between Bl0-C3H strain combination. 
t Syngeneic (C3H-C3H) control. 
t See Materials and Methods for details. 
§ Dose of 200 IL9 IP on day 2 posttransplantation. 
" Dose of 200 ",g IP; 10 doses starting from day 2 and every 72 hours thereafter. 
~ Dose of 250 ",g I M on Days O. 2. and 4 posttransplantation. 
# 250 ",g 1M; ten doses starting on day 2 and every 72 hours thereafter. 
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animals in groups Band C were primarily due to accretion 
of alpha-smooth-muscle-actin (a-smA)-positive cells. 
Use of CfLA4-lg fusion protein alone either in a single 
(group D) or in 10 (group E) consecutive doses did not 
preclude the eventual development of CR (Table 1). Sim-
ilarly, the use of anti-gp39 MAb alone (group F) was 
ineffective in averting the development of posttransplant 
vasculopathy. Conversely, treatment of the recipients with a 
short course of CfLA4-Ig fusion protein and anti-gp39 
MAb (group G) resulted in marked diminution in morpho-
logic changes pathognomonic of CR. Complete freedom 
from the development of posttransplant vasculopathy was, 
however, achieved in animals in whom treatment resulted in 
a more prolonged and stable blockade of the CD28/B7 and 
CD40/CD40L costimulatory pathways (group H; Table 1). 
The observations reported suggest that, for the preven-
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tion of arteriopathy in clinical organ transplant recipients. 
prolonged perioperative disruption of costimulatory signal-
ing may be required. This could be achieved hy contempo-
raneous use of CfLA4-Ig fusion protein and anti-gp39 
MAb. which. when used in appropriate doses. block signal-
ing between CD28/B7 and CD40/CD40L pathways. respec-
tively, and mitigate development of CR. 
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